Exelixis
EXEL
#1786
Rank
ยฃ7.57 B
Marketcap
ยฃ26.51
Share price
-0.09%
Change (1 day)
53.77%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): ยฃ0.22

According to Exelixis's latest financial reports the company's current EPS (TTM) is ยฃ0.23. In 2022 the company made an earnings per share (EPS) of ยฃ0.46 a decrease over its 2021 EPS that were of ยฃ0.60.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)ยฃ0.22-51.33%
2022ยฃ0.46-22.97%
2021ยฃ0.60100%
2020ยฃ0.30-65.09%
2019ยฃ0.85-53.91%
2018ยฃ1.85333.96%
2017ยฃ0.43-260.61%
2016-ยฃ0.27-58.75%
2015-ยฃ0.64-42.45%
2014-ยฃ1.125.3%
2013-ยฃ1.0643.48%
2012-ยฃ0.74-264.29%
2011ยฃ0.45-165.88%
2010-ยฃ0.68-32.54%
2009-ยฃ1.01-17.65%
2008-ยฃ1.2375.86%
2007-ยฃ0.70-25.64%
2006-ยฃ0.948.33%
2005-ยฃ0.87-42.86%
2004-ยฃ1.5230.34%
2003-ยฃ1.17-5.23%
2002-ยฃ1.23-0.65%
2001-ยฃ1.24-51.88%
2000-ยฃ2.58

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
ยฃ2.82 1,135.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
ยฃ2.56 1,022.57%๐Ÿ‡ซ๐Ÿ‡ท France
ยฃ1.47 543.02%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ3.20 1,301.34%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ11.39 4,894.71%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ11.34 4,871.87%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ1.50 556.55%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ8.05-3,629.83%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ0.68-396.51%๐Ÿ‡บ๐Ÿ‡ธ USA